MoneyWorks4Me

Ajanta Pharma informs about press release

18 Jul 2016 Evaluate

Ajanta Pharma has informed about a Press Release dated July 18, 2016, titled ‘Ajanta Pharma Announces US FDA Approval & Launch of Omeprazole and Sodium Bicarbonate Capsules in US Market’.

The above information is a part of company’s filings submitted to BSE.

Ajanta Pharma Share Price

3555.00 14.30 (0.40%)
28-Aug-2026 12:57 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1918.55
Dr. Reddys Labs. 1182.55
Cipla 1414.00
Lupin 2167.00
Zydus Lifesciences 1178.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: